RA patients are at an increased risk for cardiovascular events and death from cardiovascular disease. In the general population, and in RA patients (Jane, link to ACR2005 abstract 1901), carotid atherosclerosis (defined by identification of a thickened intima-medial or plaque using ultrasound) is highly predictive of cardiovascular events. Despite this, previous studies have not identified a clear-cut increased risk for carotid plaque in individuals with RA compared to non-RA controls.
A single nucleotide polymorphism (SNP) in the PTPN22 gene has recently been shown to associate with rheumatoid arthritis (RA) with a strength of association second only to that of the HLA region encoding the MHC class II shared epitope (SE). To date, the mechanism by which the altered PTPN22 gene contributes to the pathogenesis of RA has largely been unstudied.
Both etanercept (Enbrel) and infliximab (Remicade) have been shown to be effective in the treatment of psoriasis and psoriatic arthritis in randomized, double-blind, placebo-controlled trials.
The Food and Drug Administration (FDA) has now approved abatacept (Orencia®) for the treatment of rheumatoid arthritis (RA). It is the first approved agent to demonstrate efficacy and safety in patients with an inadequate response to TNF antagonists, as well as those with an inadequate response to MTX.
Purpose Physical inactivity is a risk factor for many diseases, including cardiovascular disease. However it is unknown whether being physically active might increase longevity in persons with and without cardiovascular disease. To address this question, Franco and colleagues (Archives of Internal Medicine, 2005; 165:2355-2360) calculated the consequences of different levels of physical activity on life […]
Beginning November 15, 2005 through May 15, 2006, individuals can enroll for the new Medicare presription drug insurance plan. Similar to other plans, the individual will pay a monthly premium and part of the cost of the presription drugs. Below is a list of resources for detailed information on this new program. The Official U.S. […]
The robust expression of pro-inflammatory cytokines by synovial macrophages and fibroblasts in RA and the relative ease of access of most affected joints make intra-articular gene therapy a compelling therapeutic possibility. Advantages include the ability to target only affected joints, reasonable assurance of delivery of therapy, and, potentially, the avoidance of adverse effects associated with […]
Mechanical forces exerted on the knee contribute to the development of knee osteoarthritis (OA). Among these, the additional torque about the knee associated with increasing leg length may predispose people of taller stature to knee OA. However, this association has received little prior investigation. In contrast to body height, which may decrease with age, knee height is relatively constant, making knee height a more appropriate surrogate for stature in the elderly.
Total knee replacement (TKR) is an effective, yet underutilized, treatment for severe knee osteoarthritis (OA). In particular, eligible minority patients tend to undergo TKR less often than white patients. The origins of these racial/ethnic disparities are incompletely understood, but may include both care-based (e.g. physician bias for recommending TKR) and patient-based (e.g. decisions not to undergo TKR if recommended) factors.
Active polyarticular juvenile rheumatoid arthritis (JRA) can result in significant joint destruction, deformity, and lifelong loss of physical function. NSAIDs, generally effective in controlling the symptoms of the pauciarticular form of JRA, are often not adequately effective in polyarticular JRA. Although many JRA patients are treated with the same DMARDs used to treat adult-onset RA (i.e. methotrexate, sulfasalazine, etc), few controlled clinical trials of DMARDs have been conducted in JRA patients.